Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis

  • China National Medical Products Administration (NMPA) approval reinforces that Cosentyx® (secukinumab) is safe and effective for children and adults with psoriasis
  • Moderate-to-severe plaque psoriasis affects more than 350,000 children worldwide1, with the physical and psychological burden disrupting important formative years2
  • Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory …
/by

Novartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeks

  • Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2
  • In key fluid-related secondary endpoints from KITE at year two, Beovu® (brolucizumab) 6 mg demonstrated greater reductions in central subfield thickness, and fewer patients had intraretinal and/or subretinal fluid versus aflibercept1
  • A majority of patients who …
/by

Asia Pacific Patient Innovation Summit examines capability building gaps of Patient Organizations

The Asia Pacific Patient Innovation Summit (APPIS) has published its first whitepaper that examines the regional landscape for patient organizations and explores existing capability building gaps. The patient community-led report, ‘Partnering with patient organizations to address the unmet needs of patient communities in the Asia Pacific region and beyond’, aims to enable a greater understanding and recognition of the seminal role of patient organizations and the patient voice in shaping the future of healthcare, while providing a series of recommendations for patient groups: 

  • …
/by

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA

Ad hoc announcement pursuant to Art. 53 LR

  • FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study
  • New Phase 3 STEER study will evaluate efficacy, safety, and tolerability of OAV-101 IT in treatment-naïve patients with SMA Type 2 aged between 2 and 18 years old, the first to study gene therapy in this patient population
  • STEER will build upon the OAV-101 IT STRONG study which demonstrated significant increases in HFMSE scores and a …
/by

Novartis receives FDA Orphan Drug Designation for NIS793 in pancreatic cancer

Novartis today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer. NIS793 is a potential first in class novel antibody specific for Transforming Growth Factor Beta (TGFβ), which is known to have an important role in metastatic pancreatic ductal carcinoma (mPDAC) and other solid tumors.

  • Pancreatic cancer has one of the lowest survival rates of any cancer, with typically late detection and poor outcomes with standard of care treatment …
/by

Novartis Financial Results – Q2 2021

Media Release

English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB) | Français (PDF 0.4 MB) 

Interim financial report (PDF …

/by

Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

Ad hoc announcement pursuant to Art. 53 LR

  • Net sales in Q2 grew +9% (cc¹, +14% USD):
    • Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21% cc) and Zolgensma (+48% cc). Kesimpta sales reached USD 66 million
    • Oncology BU grew +7% (cc, +11% USD) driven by Promacta/Revolade (+18% cc), Jakavi (+19% cc), Kisqali (+36% cc) and Tafinlar + Mekinist (+10% cc)
    • Sandoz grew +5 …
/by

In your neighborhood: a community-based approach to health equity in the US

Can a pharmaceutical company help close the racial healthcare gap in the US? Patrice Matchaba thinks so. His plans involve an initiative designed to bring about foundational change by tapping into the potential of underserved communities.

“We need to engage with the people whose problem we want to help solve, not create solutions for them,” says Matchaba, President of the Novartis US Foundation and Head of US Corporate Responsibility at Novartis.

Matchaba spent most of his two-decade career at Novartis steering experimental medicines through the drug development pipeline. He is …

/by

Beacon of Hope: Addressing health disparities through holistic community-based collective action

Black/African Americans have endured education and health disparities in the United States (US) for four centuries. Access to basic education was illegal for Black/African Americans in America, and health care where it existed was often denied. Dating back to the severe inequalities imposed by slavery, evidence suggests that the public health system in the US subsequently developed in ways that have sustained racially divided health care.1

Well-documented examples of disenfranchisement of Black/African Americans in health and science include the Tuskegee Syphilis Study, in …

/by

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

  • Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and others to address root causes of disparities in health and education
  • This collaboration will create actionable solutions to target the systemic racism that drives inequitable health outcomes and work together for health equity progress through greater diversity, equity and inclusion across the research and development ecosystem …
/by